Published in Am J Respir Crit Care Med on November 01, 2013
The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD) | NCT01151306
Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med (2015) 0.95
The role of microparticles in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.89
Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.88
Lung disease as a determinant of cognitive decline and dementia. Alzheimers Res Ther (2015) 0.84
The clinical value of serial measurement of high-sensitivity cardiac troponin T in acute exacerbations ofchronic obstructive pulmonary disease. Open Heart (2014) 0.83
COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci (Lond) (2016) 0.82
Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study. Int J Chron Obstruct Pulmon Dis (2015) 0.81
Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations. Am J Physiol Lung Cell Mol Physiol (2014) 0.81
Central arterial stiffness is increased among subjects with severe and very severe COPD: report from a population-based cohort study. Eur Clin Respir J (2015) 0.78
Alterations in the expression of the NF-κB family member RelB as a novel marker of cardiovascular outcomes during acute exacerbations of chronic obstructive pulmonary disease. PLoS One (2014) 0.78
β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol. BMJ Open (2016) 0.78
AECOPD: Acute exacerbations of chronic obstructive cardiopulmonary disease? Am J Respir Crit Care Med (2013) 0.77
Lung function and airway obstruction: associations with circulating markers of cardiac function and incident heart failure in older men-the British Regional Heart Study. Thorax (2016) 0.77
A Systematic Review of Diagnostic Biomarkers of COPD Exacerbation. PLoS One (2016) 0.77
Depression Is Associated with Readmission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc (2016) 0.77
C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations. PLoS One (2017) 0.75
Club Cell-16 and RelB as Novel Determinants of Arterial Stiffness in Exacerbating COPD Patients. PLoS One (2016) 0.75
From comorbidities of chronic obstructive pulmonary disease to identification of shared molecular mechanisms by data integration. BMC Bioinformatics (2016) 0.75
COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry. PLoS One (2016) 0.75
No association between exacerbation frequency and stroke in patients with COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Assessments of endothelial function and arterial stiffness are reproducible in patients with COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators. Drugs (2017) 0.75
B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med (2017) 0.75
Invasive coronary angiography in patients with acute exacerbated COPD and elevated plasma troponin. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Pulmonary Artery Enlargement Is Associated With Cardiac Injury During Severe Exacerbations of COPD. Chest (2016) 0.75
Differences in systemic adaptive immunity contribute to the 'frequent exacerbator' COPD phenotype. Respir Res (2016) 0.75
Executive Function, Survival, and Hospitalization in Chronic Obstructive Pulmonary Disease. A Longitudinal Analysis of the National Emphysema Treatment Trial (NETT). Ann Am Thorac Soc (2015) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J (2006) 17.53
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 10.05
Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol (2010) 9.44
Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 9.09
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax (2002) 8.77
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax (2005) 7.39
Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation (2003) 4.63
Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J (2008) 4.11
COPD exacerbations: defining their cause and prevention. Lancet (2007) 3.46
Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 3.34
Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet (1993) 3.03
Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost (2000) 2.74
Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation (2006) 2.70
Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest (2005) 2.41
Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax (2011) 2.39
Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation (2000) 2.27
Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest (2009) 2.16
Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 2.01
Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 1.87
Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. Am J Respir Crit Care Med (2012) 1.87
Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J (2007) 1.68
Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation (2005) 1.64
The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest (2011) 1.64
Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax (2011) 1.61
Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax (2012) 1.42
Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax (2011) 1.25
Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest (2008) 1.20
Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax (2007) 1.17
Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost (2009) 1.13
Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J (2012) 1.12
Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation (2002) 1.06
Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest (2009) 1.01
Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax (2012) 0.96
Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med (2011) 0.89
Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD (2011) 0.84
Mechanistic links between acute respiratory tract infections and acute coronary syndromes. J Infect (2012) 0.82
Dynamic vascular changes following intravenous antibiotics in patients with cystic fibrosis. J Cyst Fibros (2012) 0.81
Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction. Br J Clin Pharmacol (2010) 0.79
Fast in the aorta, slow in the coronaries. Cardiology (2010) 0.79
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 4.87
Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 4.73
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 2.80
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2008) 2.66
Airway and systemic inflammation and decline in lung function in patients with COPD. Chest (2005) 2.59
Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ (2004) 2.39
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med (2009) 2.17
Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest (2009) 2.16
Use and utility of a 24-hour Telephone Support Service for 'high risk' patients with COPD. Prim Care Respir J (2010) 2.14
Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest (2006) 2.06
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.90
Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis (2009) 1.85
Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 1.85
Exacerbations of chronic obstructive pulmonary disease. Respir Care (2003) 1.80
Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.75
Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.73
Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med (2008) 1.68
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur Respir J (2013) 1.62
Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med (2013) 1.62
Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. Cochrane Database Syst Rev (2012) 1.60
Integrating image quality in 2nu-SVM biometric match score fusion. Int J Neural Syst (2007) 1.50
C-reactive protein: does it predict mortality? Am J Respir Crit Care Med (2007) 1.47
Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax (2012) 1.42
Outdoor air pollution and respiratory health in patients with COPD. Thorax (2011) 1.42
Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.40
IL-1α/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One (2011) 1.37
Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med (2011) 1.32
Time course and pattern of COPD exacerbation onset. Thorax (2011) 1.30
Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci (2011) 1.27
The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med (2012) 1.26
Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J (2008) 1.26
A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health (2004) 1.17
Controversies in treatment of chronic obstructive pulmonary disease. Lancet (2011) 1.16
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2012) 1.10
Factors associated with change in exacerbation frequency in COPD. Respir Res (2013) 1.08
Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest (2005) 1.07
Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med (2009) 1.02
Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest (2009) 1.01
Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulm Med (2010) 0.99
Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis. Life Sci (2013) 0.98
Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res (2007) 0.98
Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. COPD (2007) 0.95
Viral infections in obstructive airway diseases. Curr Opin Pulm Med (2003) 0.93
25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. BMC Pulm Med (2012) 0.93
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Structural and functional co-conspirators in chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc (2007) 0.92
Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). Respir Med (2004) 0.92
Reduced lung-cancer mortality with CT screening. N Engl J Med (2011) 0.89
COPD exacerbations: causes, prevention, and treatment. Med Clin North Am (2012) 0.89
Bromelain inhibits nuclear factor kappa-B translocation, driving human epidermoid carcinoma A431 and melanoma A375 cells through G(2)/M arrest to apoptosis. Mol Carcinog (2011) 0.88
Are early life factors considered when managing respiratory disease? A British Thoracic Society survey of current practice. Thorax (2012) 0.88
Anti-inflammatory activity of Seabuckthorn (Hippophae rhamnoides) leaves. Int Immunopharmacol (2005) 0.88
Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 0.88
Natural history of successive COPD exacerbations. Thorax (2012) 0.87
Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor-kappaB and Akt activation in human cervical cancer cells. Oncol Res (2011) 0.87
Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res (2014) 0.86